Key Points
- CFO sale: Glaukos CFO Alex Thurman sold 315 shares on Nov. 25 at an average of $105 for $33,075, trimming his ownership by 0.62% to 50,488 shares (worth about $5.30M).
- Quarterly results beat expectations: the company reported EPS of -$0.16 vs. a -$0.27 consensus and revenue of $133.54M (up 38.1% year‑over‑year vs. a $122.55M estimate).
- Stock and analyst view: shares were up about 1.1% to $105.53 (market cap ~$6.06B), and analysts hold a consensus Moderate Buy rating with an average target of $119.08.
Glaukos Corporation (NYSE:GKOS - Get Free Report) CFO Alex Thurman sold 315 shares of the business's stock in a transaction on Tuesday, November 25th. The stock was sold at an average price of $105.00, for a total value of $33,075.00. Following the sale, the chief financial officer directly owned 50,488 shares in the company, valued at $5,301,240. This trade represents a 0.62% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.
Glaukos Trading Up 1.1%
Shares of NYSE:GKOS traded up $1.18 during midday trading on Thursday, reaching $105.53. The company had a trading volume of 1,075,607 shares, compared to its average volume of 1,000,006. The company has a fifty day simple moving average of $85.97 and a two-hundred day simple moving average of $91.71. The firm has a market cap of $6.06 billion, a price-to-earnings ratio of -68.53 and a beta of 0.81. Glaukos Corporation has a 1-year low of $73.16 and a 1-year high of $163.71. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.69 and a current ratio of 5.51.
Glaukos (NYSE:GKOS - Get Free Report) last posted its quarterly earnings data on Wednesday, October 29th. The medical instruments supplier reported ($0.16) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.27) by $0.11. Glaukos had a negative return on equity of 7.53% and a negative net margin of 18.65%.The firm had revenue of $133.54 million for the quarter, compared to the consensus estimate of $122.55 million. During the same quarter in the previous year, the company earned ($0.28) EPS. The business's revenue for the quarter was up 38.1% compared to the same quarter last year. Glaukos has set its FY 2025 guidance at EPS. Research analysts predict that Glaukos Corporation will post -1.08 earnings per share for the current year.
Analyst Upgrades and Downgrades
A number of equities analysts recently commented on GKOS shares. William Blair raised shares of Glaukos to a "strong-buy" rating in a research note on Thursday, July 31st. Citigroup lifted their price target on Glaukos from $110.00 to $113.00 and gave the company a "buy" rating in a report on Thursday, October 30th. BTIG Research upped their price target on Glaukos from $104.00 to $116.00 and gave the company a "buy" rating in a research report on Thursday, October 30th. The Goldman Sachs Group initiated coverage on Glaukos in a research report on Wednesday, October 1st. They set a "buy" rating and a $103.00 price objective for the company. Finally, Zacks Research cut Glaukos from a "strong-buy" rating to a "hold" rating in a research note on Friday, August 15th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $119.08.
View Our Latest Stock Report on GKOS
Institutional Investors Weigh In On Glaukos
Several large investors have recently made changes to their positions in GKOS. Zurcher Kantonalbank Zurich Cantonalbank raised its position in Glaukos by 7.8% during the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 16,099 shares of the medical instruments supplier's stock valued at $1,584,000 after acquiring an additional 1,160 shares in the last quarter. LPL Financial LLC raised its holdings in shares of Glaukos by 25.1% during the 1st quarter. LPL Financial LLC now owns 15,775 shares of the medical instruments supplier's stock valued at $1,553,000 after purchasing an additional 3,163 shares in the last quarter. XTX Topco Ltd bought a new position in shares of Glaukos during the 1st quarter valued at $352,000. Thornburg Investment Management Inc. lifted its stake in shares of Glaukos by 10.6% in the 1st quarter. Thornburg Investment Management Inc. now owns 50,430 shares of the medical instruments supplier's stock valued at $4,963,000 after purchasing an additional 4,847 shares during the last quarter. Finally, Bayforest Capital Ltd bought a new stake in Glaukos in the first quarter worth $141,000. Institutional investors own 99.04% of the company's stock.
Glaukos Company Profile
(
Get Free Report)
Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
